[{"orgOrder":0,"company":"Immunome","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"IMM-BCP-01","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Immunome","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Immunome \/ U.S. Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Immunome \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Immunome","sponsor":"Abzena Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Immunome","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Immunome \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Immunome"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Immunome \/ U.S. Department of Defense","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IMM-ONC-01","moa":"IL-38 ant","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"IMM20324","moa":"Interleukin-38","graph1":"Oncology","graph2":"Undisclosed","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Boston University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM20184","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Boston University","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Boston University"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 virus protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Fox Chase Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-ONC-01","moa":"IL-38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Fox Chase Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Fox Chase Cancer Center"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-BCP-01","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"University of Vermont Larner College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM-ONC-01","moa":"IL-38","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ University of Vermont Larner College of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ University of Vermont Larner College of Medicine"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":1.3,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.3,"dosageForm":"","sponsorNew":"Immunome \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ AbbVie"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Not Applicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Morphimmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Immunome"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"IMM-ONC-01","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"Immunome","sponsor":"Morphimmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Immunome"},{"orgOrder":0,"company":"Immunome","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"IMM20320","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Immunome","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"","sponsorNew":"Immunome \/ Enavate Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Immunome \/ Enavate Sciences"},{"orgOrder":0,"company":"Immunome","sponsor":"Zentalis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ZPC-21","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0.31,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"","sponsorNew":"Immunome \/ Immunome","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Immunome"},{"orgOrder":0,"company":"Immunome","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Immunome \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ Immunome"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"IM-1021","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Immunome","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"IM-1021","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0.23000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Immunome \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ J.P. Morgan"},{"orgOrder":0,"company":"Immunome","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"AL102","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Immunome","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Immunome \/ Immunome","highestDevelopmentStatusID":"9","companyTruncated":"Immunome \/ Immunome"},{"orgOrder":0,"company":"Immunome","sponsor":"Atreca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"APN-497444","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Immunome","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Immunome \/ Immunome","highestDevelopmentStatusID":"2","companyTruncated":"Immunome \/ Immunome"},{"orgOrder":0,"company":"Immunome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"IM-3050","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Immunome \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immunome \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Immunome
Details :
IM-3050, the company’s Preclinical lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein, is being investigated for the treatment of cancer indications.
Details :
Through the acquisition, Immunome have the access for AL102, a small molecule gamma secretase inhibitor currently being evaluated for desmoid tumors, and related drug candidate AL101 from Ayala.
Details :
The net proceeds will be allocated towards the development of IM-1021, a topoisomerase I inhibitor currently under evaluation for the treatment of patients afflicted with triple-negative cancer.
Details :
The net proceeds will be allocated towards the development of IM-1021, a topoisomerase I inhibitor currently under evaluation for the treatment of patients afflicted with triple-negative cancer.
Details :
Through the acquisition, Immunome will have the access for AL102, a small molecule gamma secretase inhibitor currently being evaluated for desmoid tumors, and related drug candidate AL101 from Ayala.
Details :
Through the acquisition, Immunome aims to utilize Atreca's APN-497444, a Glycan receptor inhibitor currently in the discovery stage, for the treatment of gastrointestinal cancers.
Details :
The combined company will feature a synergistic platform which is expected to enable the development of best-in-class targeted cancer therapies across multiple modalities.
Details :
The net proceeds will be used to continue development of the lead assets in Immunome’s combined pipeline including, IMM20320, a novel anti-IL-38 mAb, and to continue to advance the company’s platforms.
Details :
The combined company will feature a synergistic platform which is expected to enable the development of best-in-class targeted cancer therapies across multiple modalities.
Reset All
